Icaz Lp

Isradipine, the active ingredient in Icaz Lp, is a calcium channel blocker presented as a tablet for oral use. It is prescribed to lower elevated blood pressure in adults with hypertension. GNH USA supplies Icaz Lp as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Isradipine belongs to the calcium‑channel blocker class and is used to manage conditions related to high blood pressure.

Hypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular complications.

Isradipine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness. - Dizziness or light‑headedness, especially after standing. - Peripheral edema: swelling of ankles or feet. - Nausea: occasional upset stomach. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure. - Myocardial infarction: rare heart attack events. - Hepatic dysfunction: abnormal liver enzymes. - Allergic reactions: rash, pruritus, or urticaria. - Angioedema: swelling of face, lips, or throat. - Cardiac arrhythmias: irregular heart rhythms.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Blood pressure monitoring: check regularly to avoid excessive hypotension. - Hepatic function: assess liver enzymes in patients with liver disease. - Heart failure: use cautiously in patients with reduced ejection fraction. - Concomitant antihypertensives: adjust doses to prevent additive effects. - Discontinuation: avoid abrupt stopping; taper if needed. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Isradipine can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Other potent antihypertensives: may cause excessive blood pressure drop. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase isradipine plasma levels. - Grapefruit juice: enhances drug exposure, raising risk of hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce isradipine effectiveness. - NSAIDs: may blunt antihypertensive response. - Beta‑blockers: can accentuate bradycardia and AV‑block risk.